Lipoprotein(a) Management

Introduction to Lipoprotein(a)

The American College of Cardiology considers Lipoprotein(a) elevated when it exceeds 30 mg/dL, with significant risk starting at >50 mg/dL, and primary treatment consists of aggressive reduction of LDL cholesterol with high-intensity statins, potentially combined with niacina or PCSK9 inhibitors for high-risk patients 1
The European guidelines define a significant risk at >50 mg/dL, affecting approximately 20% of the global population 1, 2

The traditional threshold value is >30 mg/dL, representing the 75th percentile in Caucasian populations and the point at which cardiovascular risk begins to increase demonstrably 1
Risk increases progressively with higher levels, with particularly high risk at >100 mg/dL 1
Lipoprotein(a) levels are determined genetically by 70-90% and remain relatively stable throughout life, so a single measurement is generally sufficient 1

The primary therapeutic strategy is aggressive reduction of LDL cholesterol, as randomized trials demonstrate that when Lipoprotein(a) is elevated, cardiovascular event rates remain higher at any achieved LDL-C level, confirming residual risk mediated by Lipoprotein(a) 1
Target LDL-C <70 mg/dL for patients with elevated Lipoprotein(a) 1
Initiate with high-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily) 1
Niacin is currently the most effective conventional drug, reducing Lipoprotein(a) by 30-35% at doses up to 2000 mg/day 1, 3
PCSK9 inhibitors (evolocumab or alirocumab) reduce Lipoprotein(a) by 25-30% and provide a dual benefit: 50-60% reduction in LDL-C and 25-30% reduction in Lipoprotein(a) 1, 3

In patients with chronic kidney disease, Lipoprotein(a) levels are substantially increased and progress with worsening renal function, and Lipoprotein(a) is an independent predictor of incident coronary events and mortality 4, 1
Children with elevated Lipoprotein(a) have a quadrupled risk of acute ischemic stroke, and the risk of recurrent ischemic strokes increases more than 10-fold in patients with Lipoprotein(a) >90th percentile 4, 1

Lipoprotein apheresis reduces Lipoprotein(a) by up to 80% and is the most effective treatment currently available 4, 1, 3
Indications include patients with Lipoprotein(a) >60 mg/dL, controlled LDL-C, and recurrent or progressive cardiovascular disease despite optimal therapy 4, 1

Do not assume that achieving LDL-C targets eliminates cardiovascular risk, as elevated Lipoprotein(a) confers residual risk even with optimal LDL-C control 1
Do not rely exclusively on LDL-C levels for cardiovascular risk assessment without considering Lipoprotein(a), as this may underestimate total risk in affected individuals 2